Skip to content

Riluzole (Glentek) in patients with SpinoCerebellar Ataxia type 7: a randomized, doubleblind, placebo-controlled pilot trial with a lead in phase

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518962-29-00
Acronym
AIFA-2016-02365063
Enrollment
24
Registered
2024-11-27
Start date
2021-12-07
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinocerebellar ataxia type 7 (SCA7)

Brief summary

The primary endpoints will be the proportion of patients with stable SARA score and visual acuity expressed as log MAR units at 18 months, in comparison with the same parameters as mean of t0-t3-t6 evaluations .

Detailed description

The secondary endpoint will be quantitative ophthalmologic assessments (via a Farnsworth D15 Arrangement Test, Visual evoked, Electroretinography, Optical Coherence tomography, Computerized visual field examination) and SARA score as continuous values at 18 months, in comparison with the same parameters calculated for each patient as mean of t0-t3-t6 evaluations, The safety profile will be assessed through the recording, reporting and analyzing of baseline medical conditions, adverse events, physical examination findings including laboratory tests.

Interventions

DRUGGlentek 50 mg filmtabletten
DRUGPlacebo Riluzole is a hard gelatin capsule filled with the inert excipient microcrystalline cellulose (Avicel® PH200).

Sponsors

Universita Degli Studi Di Roma La Sapienza
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoints will be the proportion of patients with stable SARA score and visual acuity expressed as log MAR units at 18 months, in comparison with the same parameters as mean of t0-t3-t6 evaluations .

Secondary

MeasureTime frame
The secondary endpoint will be quantitative ophthalmologic assessments (via a Farnsworth D15 Arrangement Test, Visual evoked, Electroretinography, Optical Coherence tomography, Computerized visual field examination) and SARA score as continuous values at 18 months, in comparison with the same parameters calculated for each patient as mean of t0-t3-t6 evaluations, The safety profile will be assessed through the recording, reporting and analyzing of baseline medical conditions, adverse events, physical examination findings including laboratory tests.

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026